William A. Corum Jr.

Array ( [id] => 19113129 [patent_doc_number] => 20240124879 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => RNAI AGENT FOR INHIBITING HBV EXPRESSION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/267885 [patent_app_country] => US [patent_app_date] => 2021-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9955 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18267885 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19462421 [patent_doc_number] => 20240316090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES (TALENS) TARGETING HBV [patent_app_type] => utility [patent_app_number] => 18/259535 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41211 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 197 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18259535 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18921462 [patent_doc_number] => 20240024466 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => LIPIDOID COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/265561 [patent_app_country] => US [patent_app_date] => 2021-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18073 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -120 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18265561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18844489 [patent_doc_number] => 20230406893 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => PAM RESTRICTION-FREE ADENINE BASE EDITOR FUSED PROTEIN AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/037689 [patent_app_country] => US [patent_app_date] => 2021-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8295 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18037689 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18831110 [patent_doc_number] => 20230399635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => RNA-Editing Compositions and Methods of Use [patent_app_type] => utility [patent_app_number] => 18/036176 [patent_app_country] => US [patent_app_date] => 2021-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 91294 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -133 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18036176 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18829696 [patent_doc_number] => 20230398220 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => SIRNA-NANOBOWL-MEDIATED INTERVENTION OF COVID-19 [patent_app_type] => utility [patent_app_number] => 18/251227 [patent_app_country] => US [patent_app_date] => 2021-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25643 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18251227 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18844871 [patent_doc_number] => 20230407275 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => ENHANCEMENT OF PREDICTABLE AND TEMPLATE-FREE GENE EDITING BY THE ASSOCIATION OF CAS WITH DNA POLYMERASE [patent_app_type] => utility [patent_app_number] => 18/251384 [patent_app_country] => US [patent_app_date] => 2021-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6257 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18251384 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19449238 [patent_doc_number] => 20240309368 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => TARGETED RNA EDITING BY LEVERAGING ENDOGENOUS ADAR USING ENGINEERED RNAS [patent_app_type] => utility [patent_app_number] => 18/272009 [patent_app_country] => US [patent_app_date] => 2021-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38778 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18272009 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17702894 [patent_doc_number] => 20220202900 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => COMPOSITIONS AND METHODS FOR CRISPR/CAS9 KNOCK-OUT OF CD33 IN HUMAN HEMATOPOIETIC STEM / PROGENITOR CELLS FOR ALLOGENIC TRANSPLANTATION IN PATIENTS WITH RELAPSED - REFRACTORY ACUTE MYELOID LEUKEMIA [patent_app_type] => utility [patent_app_number] => 17/432880 [patent_app_country] => US [patent_app_date] => 2020-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36988 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17432880 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19171012 [patent_doc_number] => 20240156986 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN, and PLOD1 genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-COL1A1, or Escherichia coli strain SCS110-AF/VTvaf17-COL1A2, or Escherichia coli strain SCS110-AF/VTvaf17-P4HA1, or Escherichia coli strain SCS110-AF/VTvaf17-P4HA2, or Esch [patent_app_type] => utility [patent_app_number] => 18/269793 [patent_app_country] => US [patent_app_date] => 2019-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27991 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18269793 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19379454 [patent_doc_number] => 20240269324 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of ANG, ANGPT1, VEGFA, FGF1, HIF1a, HGF, SDF1, KLK4, PDGFC, PROK1, and PROK2 genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-ANG, or Escherichia coli strain SCS110-AF/VTvaf17-ANGPT1, or Escherichia coli strain SCS110-AF/VTvaf17-VEGFA, or Escherichia coli strain SCS110-AF/VTvaf17-FGF [patent_app_type] => utility [patent_app_number] => 18/269791 [patent_app_country] => US [patent_app_date] => 2019-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29072 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18269791 [rel_patent_id] =>[rel_patent_doc_number] =>)